This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Carisbamate
- DrugBank Accession Number
- DB12338
- Background
Carisbamate has been investigated in Alcohol Abuse, Substance Abuse, and Alcohol Dependence.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Carisbamate (DB12338)
- Weight
- Average: 215.63
Monoisotopic: 215.0349209 - Chemical Formula
- C9H10ClNO3
- Synonyms
- Carisbamate
- External IDs
- JNJ-10234094
- RWJ-333369-000
- YKP-509
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Carisbamate is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Carisbamate. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Carisbamate. Aclidinium Carisbamate may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Carisbamate. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Carisbamate. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Carisbamate. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Carisbamate. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Carisbamate. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Carisbamate. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- ATC Codes
- N03AX19 — Carisbamate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Halobenzenes
- Direct Parent
- Chlorobenzenes
- Alternative Parents
- Aryl chlorides / Carbamate esters / Secondary alcohols / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds / Aromatic alcohols
- Substituents
- Alcohol / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Carbamic acid ester / Carbonyl group / Chlorobenzene / Hydrocarbon derivative / Organic nitrogen compound
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P7725I9V3Z
- CAS number
- 194085-75-1
- InChI Key
- OLBWFRRUHYQABZ-MRVPVSSYSA-N
- InChI
- InChI=1S/C9H10ClNO3/c10-7-4-2-1-3-6(7)8(12)5-14-9(11)13/h1-4,8,12H,5H2,(H2,11,13)/t8-/m1/s1
- IUPAC Name
- (2S)-2-(2-chlorophenyl)-2-hydroxyethyl carbamate
- SMILES
- NC(=O)OC[C@@H](O)C1=CC=CC=C1Cl
References
- General References
- Not Available
- External Links
- PubChem Compound
- 6918474
- PubChem Substance
- 347828597
- ChemSpider
- 5293671
- ChEBI
- 135966
- ChEMBL
- CHEMBL2087003
- ZINC
- ZINC000030691363
- Wikipedia
- Carisbamate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Complex Partial Seizures / Epilepsies / Epilepsy, Complex Partial / Epilepsy, Localization Related 1 3 Completed Treatment Epilepsy, Complex Partial / Epilepsy, Partial, Motor / Epilepsy, Simple Partial / Focal Motor Epilepsy 2 3 Recruiting Treatment Lennox Gastaut Syndrome (LGS) / Seizures 1 3 Terminated Treatment Epilepsies / Seizures 1 2 Completed Treatment Diabetic Mononeuropathy / Diabetic Neuropathy, Painful; Diabetic Neuropathies / Neuralgia, Diabetic / Polyneuropathies, Diabetic 1 2 Completed Treatment Diabetic Neuropathies 1 2 Completed Treatment Essential Tremor, Movement Disorders 1 2 Completed Treatment Herpes Zoster / Neuralgia / Postherpetic Neuralgia 1 1 Active Not Recruiting Basic Science Lennox Gastaut Syndrome (LGS) 1 1 Completed Treatment Healthy Subjects (HS) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 2.15 mg/mL ALOGPS logP 0.94 ALOGPS logP 1.29 ChemAxon logS -2 ALOGPS pKa (Strongest Acidic) 13.43 ChemAxon pKa (Strongest Basic) -3.5 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 72.55 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 51.47 m3·mol-1 ChemAxon Polarizability 20.38 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 22:00 / Updated at February 21, 2021 18:53